Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor

Melanoma Research

Volumn 14, Issue 1, 2004, Pages 13-21

  Ozen, Mustafa ^a,b   Medrano, Estela E ^a   Ittmann, Michael ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokinesis, adenovirus; Fibroblast growth factors; G2; Melanoma; Receptors

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN P21;

ADENOVIRUS; ARTICLE; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CYTOKINESIS; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; TUMOR CELL; VIRUS INFECTION; WESTERN BLOTTING;

EID: 1642331860     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200402000-00003     Document Type: Article

References (31)

1. Sauter ER, Herlyn M. Molecular biology of human melanoma development and progression. Mol Carcinog 1998; 23:132-143.
2. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62:4663-4670.
3. Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988; 107:1611-1619.
4. Lee ST, Strunk KM, Spritz RA. A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene 1993; 8:3403-3410.
5. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 1991; 97:20-26.
6. Birck A, Kirkin AF, Zeuthen J, Hou-Jensen K. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 1999; 9:375-381.
7. Albino AP, Davis BM, Nanus DM. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res 1991; 51:4815-4820.
8. Ahmed NU, Ueda M, Ito A, Ohashi A, Funasaka Y, Ichihashi M. Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res 1997; 7:299-305.
9. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995; 60:129-136.
10. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989; 8:3685-3691.
11. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3:887-893.
12. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988; 3:177-186.
13. Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R. Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol 1989; 109:3115-3128.
14. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999; 18:6469-6476.
15. Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M. Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol 2001; 158:943-953.
16. Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000; 156:193-200.
17. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Disruption of fibroblast growth factor receptor signaling leads to G2 arrest and cell death in prostate cancer cells. J Natl Cancer Inst 2001; 93:1783-1790.
18. Guerra L, Slavutsky I, Larripa I, Mordoh J, Medrano EE. Characterization of IIB-Mel-J, a new and highly heterogeneous human melanoma cell line. Pigment Cell Res 1989; 2:504-509.
19. Medrano EE, Nordlund JJ. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95:441-445.
20. Li Y, Basilico C, Mansukhani A. Cell transformation by fibroblast growth factors can be suppressed by truncated fibroblast growth factor receptors. Mol Cell Biol 1994; 14:7660-7669.
21. Giri D, Ropiquet F, Ittmann M. Alterations in expression of FGF2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5:1063-1071.
22. Giri D, Ozen M, Ittmann M. lnterleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159:2159-2165.
23. O'Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. Trends Cell Biol 2000; 10:296-303.
24. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-1501.
25. Yayon A, Ma Y, Safran M, Klagsbrun M, Halaban R. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases. Oncogene 1997; 14:2999-3009.
26. Rooney RJ. Cell cycle attenuation by p120E4F is accompanied by increased mitotic dysfunction. Cell Growth Differ 2001; 12:505-516.
27. Zhang Y, Wang Z, Ravid K. The cell cycle in polyploid megakaryocytes is associated with reduced activity of cyclin B1-dependent cdc2 kinase. J Biol Chem 1996; 271:4266-4272.
28. Yokoe H, Masumi-Fukazawa A, Sunohara M, Tanzawa H, Sato K, Sato T, Fuse A. Induction of polyploidization in the human erythroleukemia cell line (HEL) by protein kinase inhibitor (K252a) and the phorbol-ester TPA. Leuk Lymphoma 1997; 25:333-343.
29. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 20:1803-1815.
30. Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 2001; 276:42971-42977.
31. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-4160.